Shukaib Arslan on Muck Rack

Shukaib Arslan

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shukaib

Contact Shukaib, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis - Bone Marrow Transplantation

|
By Amandeep Salhotra, Karamjeet Singh Sandhu, Haris Ali, Ibrahim Aldoss, Shukaib Arslan, Paul Koller, Amanda L. Blackmon, Pamela S Becker, Vinod Pullarkat, Andrew S. Artz, Stephen J. Forman
| Nature Verified
Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is increasingly offered as a consolidation strategy for older/infirm patients with acute myeloid leukemia (AML). Fludarabine/melphalan (Flu/Mel) conditioning is associated with effective disease control but results in significant toxicity and non-relapse mortality (NRM) when combined with calcineurin-inhibitors plus methotrexate or mycophenolate mofetil.
Open in Who Shared Issue with article?

Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T‐cell precursor acute lymphoblastic leukaemia

|
By Vaibhav Agrawal, Shukaib Arslan, Hoda Pourhassan, Paul Koller
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT The authors have no conflicts of interest to declare. REFERENCES 1, , , , . Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 2012; 119(1): 34–43. 2, . Management of adults with T-cell lymphoblastic leukemia. Blood. 2017; 129(9): 1134–1142. 3, , , , , , et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10(2): 147–156. 4, , , , , , et al.
Open in Who Shared Issue with article?

Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect - Bone Marrow Transplantation

|
By Paul Koller, Tamer Othman, Amanda L. Blackmon, Shukaib Arslan, Ibrahim Aldoss, Haris Ali, Amandeep Salhotra, Andrew S. Artz, Pamela S Becker, Stephen J. Forman, Ryotaro Nakamura, Karamjeet S. Sandhu
| Nature Verified
Abstract Fludarabine and melphalan (FM) conditioning offers effective disease control with an acceptable toxicity profile. Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has improved transplant outcomes. We retrospectively reviewed patients receiving FM-based transplants with PTCy at City of Hope.
Open in Who Shared Issue with article?
See all 5 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified